# K102698 510(k) Summary

#### **General Information**

Date Prepared 10/25/2010

Classification Class II, CFR 878.4400

Product Code GEI

Common Name Electrosurgical, cutting & coagulation & accessories

Trade Name Pellevé GlideSafe™ Non-Ablative Wrinkle Treatment System

Submitter Ellman International

3333 Royal Ave Oceanside, NY 11572

Contact Information Mr. Jonathan Achenbach

Sr. Dir. R&D, Clinical & Regulatory Affairs

Ph: 516-594-3333 Fax: 516-267-6750

#### **Intended Use**

The Pellevé GlideSafe™ Non-Ablative Wrinkle Treatment System is intended for non-ablative treatment of mild to moderate facial wrinkles and rhytides for skin phototypes I-IV.

### **Predicate Devices**

Ellman Non Ablative Wrinkle Treatment System (K082834, K102368, K101967) manufactured by Ellman International

#### **Technological Characteristics**

The device is a hand-held, non-ablative wrinkle treatment handpiece available with various size electrode end effectors and a detachable cord. The electrode is spring mounted into the handle. All materials used in the manufacture of the device are suitable for the use in the device and are the same materials used in the predicate product. As with the predicated device, the device is activated using a hand or footswitch based on user preference and is intended for use with the Ellman Radio-Frequency generators (K082834) labeled for the treatment of wrinkles and rhytides.

#### Substantial Equivalence


The Pellevé GlideSafe™ Non-Ablative Wrinkle Treatment System is as safe and effective as the Ellman Non Ablative Wrinkle Treatment System. The Pellevé GlideSafe™ Non-Ablative Wrinkle Treatment System has the same indication for use, technological characteristics, and principles of operation as its predicate device. The minor technological improvements made to the device from the previous generation predicate device do not alter the fundamental scientific

technology of the device and raise no new issues of safety or effectiveness. Thus, the Pellevé GlideSafe™ Non-Ablative Wrinkle Treatment System is substantially equivalent.

## **Performance Data**

All appropriate testing has been performed and all components, subassemblies, and/or full devices met the required specifications for the completed tests. In all instances, the Pellevé GlideSafe<sup>TM</sup> Non-Ablative Wrinkle Treatment System functioned as intended and in conformance with anticipated results.

# DEPARTMENT OF HEALTH & HUMAN SERVICES





Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

Ellman International Inc. % Mr. Jonathan Achenbach 3333 Royal Ave. . . Oceanside, NY 11572

JAN E M

Re: K102698

Trade Name: Pellevé Glidesafe Non-Ablative Wrinkle Treatment System

Regulation Number: 21 CFR 878.4400

Regulation Name: Electrosurgical cutting and coagulation device and accessories

Regulatory Class: Class II

Product Code: GEI

Dated: December 29, 2010 Received: January 3, 2011

Dear Mr. Achenbach:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

Sincerely yours,

Mark N. Melkerson

Director

Division of Surgical, Orthopedic,

and Restorative Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

# "INDICATIONS FOR USE" Statement

510(k) Number (if known):	K102698	
Device Name: Pellevé Gl	lideSafe™ Non-Ablative Wri	inkle Treatment System
The Device has the following	ng "Indications for Use":	
Non-ablative treatment of	mild to moderate facial wrinkles	and rhytides for skin phototypes I-IV
Prescription Use X	OR	Over The Counter Use
(per 21 CFR 801.109)	g.	Over-The Counter Use
(PLEASE DO NOT WRITE BEI	LOW THIS LINE-CONTINUE ON ANC	OTHER PAGE IF NEEDED)
	·	
Cor	ncurrence of CDRH, Office of Device	e Evaluation (ODE)
Optional Format 1-2-96)		
	(Division Sign-Off) Division of Surgical, Orth and Restorative Devices	dopedic,
	510(k) Number K10	52698

510(k) Number\_